Repeat Dose Study in Male Healthy Volunteer Smokers

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 1

Conditions

Pulmonary Disease, Chronic Obstructive

Treatments

Drug: Placebo

Drug: SB-656933

Study type

Interventional

Funder types

Industry

Identifiers

NCT00615576

CR2111256

Details and patient eligibility

About

This is a 4 to 6 week study to look at the safety and PK profile of SB656933 in healthy male smokers

Enrollment

13 patients

Sex

Male

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy adult male smokers who are between 18-65 years of age with normal genitourinary anatomy based on physical examination.
The subjects should have a normal colour Doppler epididymal ultrasound (normal blood flow and epididymal morphology) at screening.
The first 10 mL of urine voided (VB1) should be normal at screening and pre-dose.
Male subjects must agree to abstain from or use a condom during sexual intercourse with pregnant females; or use a condom/spermicide, in addition to having their female partner use another form of contraception, such as an IUD, diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants or a tubal ligation, if engaging in sexual intercourse with a female partner who could become pregnant. This criterion must be followed from the time of the first dose of study medication until 84 days after the last dose of study medication.
The subject has a QTc(B) <450msec at screening or prior to dosing
Body weight = 50 kg (110 pounds) and body mass index (BMI) between 19 and 30 inclusive where: BMI =weight in kg/(height in meters)2
Healthy male smokers must smoke more than 10 cigarettes per day, for at least 2 months prior to screening and less than 30 cigarettes per day at the time of enrolment.
Subjects with Forced Expiratory Volume (FEV1)=80% predicted and FEV1/Forced Vital Capacity (FVC) ratio=0.7.
Signed and dated written informed consent prior to admission to the study
The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.

Exclusion criteria

Any clinically relevant abnormality identified on the screening medical assessment, laboratory examination, or 12-lead ECG.
The subject has liver function tests (LFT) elevated above the reference range at pre-study screening that remain elevated with a repeat LFT (to be discussed with the sponsor, if necessary).
Subjects with absolute neutrophil count (ANC) = 2.0x109/L.
Subjects who have previously been exposed to testicular radiotherapy.
Subjects who have had previous testicular or prostate surgery including vasectomy.
History of prostatitis, epididymitis, epididymal cysts, structural abnormalities or testicular cancer.
Subjects with abnormalities of the renal tract, renal stones or history of Urinary Tract Infections (UTI's).
Positive drug or alcohol test at screening or prior to dosing.
Positive HIV, Hepatitis B surface antigen or Hepatitis C antibody at screening
Use of prescription or non-prescription medication in the last 7 days or 5 half-lives (whichever is longer) , particularly drugs that are P450 CYP3A4, CYP2B6, CYP2C8 or OATP1B1 substrates with a narrow therapeutic index , and including vitamins and herbal remedies such as St John's Wort prior to dose of study medication.
Consumption of grapefruit or grapefruit juice within seven days prior to the first dose of study medication.
Donation of blood in excess of 500 mL within a 56 day period prior to dosing.
Exposure to more than 3 new chemical entities within 12 months prior to the first dosing day.
Participation in a trial with any drug within 3 months before the start of the study or participation in a trial with a new chemical entity within 4 months before the start of the study.
Are receiving treatment for smoking cessation.
Are using tobacco products other than cigarettes (e.g. pipes, cigars, snuff, chewing tobacco).